Neurological injury and disease often involve more than isolated neuron damage. These studies highlight how oxidative stress, inflammation, immune disruption, and systemic changes may shape recovery. Hesperetin protected neurons after stroke-related ischemia-reperfusion injury by reducing ferroptosis and inflammation, while spinal cord injury was shown to trigger rapid microbiome disruption and widespread immune and metabolic changes across the body.
The third study focuses on P2X7 receptors, which may contribute to chronic neuroinflammation in neurodegenerative diseases by activating microglia and inflammatory signaling. Together, these findings point to a broader view of neuroprotection: supporting the nervous system may require targeting not only injured neurons, but also the inflammatory, metabolic, and immune systems that influence how damage progresses.
1. Hesperetin alleviates cerebral ischemia–reperfusion injury by suppressing neuronal ferroptosis
Hesperetin helped protect neurons after cerebral ischemia-reperfusion injury by reducing oxidative stress, inflammation, and iron-driven ferroptosis. It restored GSH and GPX4 activity while lowering ACSL4, ROS, and lipid peroxidation in cell and mouse models.
2. Spinal cord injury induces acute microbiome shock and system‐wide transcriptomic reprogramming
Spinal cord injury triggered an acute “microbiome shock” within 12 hours, followed by widespread immune and metabolic gene changes across multiple organs. These findings highlight the need for phase-specific strategies that support gut and systemic recovery after SCI.
3. P2X7 receptors as targets for neuroprotection
P2X7 receptors may help drive chronic neuroinflammation across neurodegenerative diseases by activating microglia and inflammasome signaling. Blocking these receptors shows neuroprotective potential in preclinical models, especially when paired with other disease-targeted therapies.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
